Amphastar P (AMPH)vsUnited Therapeutics Corporation (UTHR)
AMPH
Amphastar P
$21.78
+5.56%
HEALTHCARE · Cap: $927.72M
UTHR
United Therapeutics Corporation
$541.83
+0.40%
HEALTHCARE · Cap: $23.07B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 340% more annual revenue ($3.17B vs $720.53M). UTHR leads profitability with a 40.6% profit margin vs 11.0%. UTHR appears more attractively valued with a PEG of 2.25. UTHR earns a higher WallStSmart Score of 57/100 (C).
AMPH
Buy50
out of 100
Grade: C-
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+9.6%
Fair Value
$31.64
Current Price
$21.78
$9.86 discount
Margin of Safety
+2.4%
Fair Value
$487.70
Current Price
$541.83
$54.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
0.4% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMPH
The strongest argument for AMPH centers on Price/Book, P/E Ratio.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : AMPH
The primary concerns for AMPH are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
AMPH profiles as a value stock while UTHR is a declining play — different risk/reward profiles.
AMPH carries more volatility with a beta of 0.90 — expect wider price swings.
AMPH is growing revenue faster at 0.4% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 50/100), backed by strong 40.6% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amphastar P
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?